glp·helper
glphelper.com/tirzepatide/north-carolina/high-point
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in High Point, NC

Verified Tirzepatide providers in High Point, NC. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
28
as of today
§ 02Provider directory: North Carolina
28 of 28 shown

Find a Tirzepatide provider in North Carolina.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by North Carolina city · /tirzepatide/north-carolina/{city}
§ 03Getting Tirzepatide in High Point
28 providers · High Point, NC

How to get Tirzepatide in High Point.

28 GLP-1 prescribers and 7 local resource types are on record for High Point, plus 3 nearby towns in the directory.

Prescribers in High Point
28 prescribers
28 GLP-1 prescribers in High Point, most listed as Family Medicine (12), Internal Medicine (8) and Internal Medicine, Endocrinology, Diabetes & Metabolism (6). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Greensboro (32 providers), Winston-Salem (27 providers) and Burlington (28 providers).
Around the prescription in High Point
7 listed nearby
35 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near High Point.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in High Point

High Point, North Carolina has a population of 114,059 people. The adult obesity rate in High Point is an age-adjusted estimate of 38.2%, 3.7 percentage points above the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 11.9% of adults in High Point. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 25.5% of adults in High Point.

of High Point adults have obesity
38.2%
diagnosed diabetes
11.9%
no regular physical activity
25.5%

Age-adjusted estimates for High Point, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s and fertility
§ 05Support around Tirzepatide in High Point
6 gyms

The prescription is one part. Here is the rest, in High Point.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near High Point, NC, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.5 on Google · 803 reviews
1116 Eastchester Dr Ste 123
Website
336 CrossFit
GYM
5.0 on Google · 214 reviews
3700 N Main St Ste 113
Website
Full Time Fitness
GYM
4.9 on Google · 92 reviews
4008 Mendenhall Oaks Pkwy Ste 109
Website
TL Fitness
GYM
5.0 on Google · 47 reviews
1800 N Main St #130
Website
Archdale Fitness 24-7
GYM
4.4 on Google · 33 reviews
10134 N Main St
High Point CrossFit
GYM
4.8 on Google · 30 reviews
1809 Eastchester Dr
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

O2 Fitness
FITNESS
4.8 on Google · 2716 reviews
4113 Brian Jordan Pl
Website
Sportscenter Athletic Club
FITNESS
4.5 on Google · 179 reviews
3811 Samet Dr
Website
Back & Bi’s Gym 24/7
FITNESS
4.6 on Google · 50 reviews
211 Swathmore Ave
Website
Edge Fitness LLC - High Point
FITNESS
4.9 on Google · 38 reviews
5250 High Point Rd
Website
MJ Fit Training & Performance
FITNESS
5.0 on Google · 7 reviews
506 Idol St
The FIIT Society
FITNESS
5.0 on Google · 6 reviews
1677 Westchester Dr
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in North Carolina

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]